This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muller, M. Articles by Lamberts, S. W. J. Search for Related Content PubMed PubMed Citation Articles by Muller, M. Articles by Lamberts, S. W. J. Related Collections Male Endocrinology

Effects of Dehydroepiandrosterone and Atamestane Supplementation on Frailty in Elderly Men

Julius Center for Health Sciences and Primary Care (M.M., Y.T.v.d.S., D.E.G.) and Department of Geriatrics (M.M.), University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; and Department of Internal Medicine (A.W.v.d.B., S.W.J.L.), Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Yvonne T. van der Schouw, Ph.D., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Room Stratenum 6.131, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: y.t.vanderschouw{at}umcutrecht.nl.

Background: It has been suggested that the age-related decline of androgens in men plays a distinct role in the development of several aspects of frailty. Therefore, hormone replacement might improve the course of frailty by increasing lean body mass and muscle strength, decreasing fat mass, and improving the subjective quality of life.

Objective: The objective of the study was to assess whether hormone replacement with dehydroepiandrosterone (DHEA) and/or atamestane might improve the course of frailty.

Design: This was a double-blind, randomized, controlled trial.

Setting: The study was conducted in the general community.

Participants: Participants included 100 nonhospitalized, nondiseased, independently living men, aged 70 yr and over with low scores on strength tests. Seventeen participants did not complete the trial.

Intervention: Subjects were randomly assigned to one of four intervention arms: atamestane (100 mg/d) and placebo, DHEA (50 mg/d) and placebo, a combination of atamestane (100 mg/d) and DHEA (50 mg/d), or two placebo tablets for 36 wk.

Main Outcome Measures: Physical frailty was measured by means of a specific test battery, including isometric grip strength, leg extensor power, and physical performance.

Results: The randomization was successful, and 83 (83%) men completed the intervention. There were no differences between the treatment arms and placebo group in any of the outcome measurements after intervention.

Conclusions: The results of this double-blind, randomized trial do not support the hypothesis that hormone replacement with DHEA and/or atamestane might improve the course of frailty.

This article has been cited by other articles:

				M. Voznesensky, S. Walsh, D. Dauser, J. Brindisi, and A. M. Kenny The association between dehydroepiandosterone and frailty in older men and women Age Ageing, July 1, 2009; 38(4): 401 - 406. [Abstract] [Full Text] [PDF]

				D. Liu, H. Si, K. A. Reynolds, W. Zhen, Z. Jia, and J. S. Dillon Dehydroepiandrosterone Protects Vascular Endothelial Cells against Apoptosis through a G{alpha}i Protein-Dependent Activation of Phosphatidylinositol 3-Kinase/Akt and Regulation of Antiapoptotic Bcl-2 Expression Endocrinology, July 1, 2007; 148(7): 3068 - 3076. [Abstract] [Full Text] [PDF]